Floatz logo

Adriamycin

Ovarian Disorder

Innovent Biologics (Suzhou) Co. Ltd.Small moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Ovarian Disorder cohort.

Asset / SponsorPhaseRating
Irinotecan
Xiaoxiang Chen
Phase 3BB
Carboplatin
Fujian Cancer Hospital
Phase 3BB
Olaparib
Xiaoxiang Chen
Phase 2BB
Pembrolizumab
Sheba Medical Center
Phase 2B
ibi354
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3B

View all 24 →

Same molecule, other indications

Adriamycin is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →